Journal of Clinical Oncology
Articles in this Issue
Clinical activity of immune checkpoint inhibitors in patients with advanced sarcomas: A retrospective single-center experience.
e23569 Background: Sarcomas are rare mesenchymal malignancies with poor outcomes in metastatic disease. Efficacy of immune...
A phase 2 study of fruquintinib combined with sintilimab and chidamide in refractory MSS metastatic colorectal cancer: Preliminary efficacy and safety.
2631 Background: Microsatellite stable (MSS) metastatic colorectal cancer (mCRC) has limited response to immune checkpoint...
Real-world patient characteristics, outcomes, and resource utilization of chimeric antigen receptor (CAR) T cell therapy across Foundation for the Accreditation of Cellular Therapy (FACT) and non-FACT treatment centers in large B-cell lymphoma (LBCL).
7023 Background: CAR T cell therapy has transformed the LBCL treatment landscape and is now being offered in some non-FACT...
Prognostic and predictive impact of baseline gene expression (exp) in the NATALEE trial of adjuvant (adj) ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in HR+/HER2− early breast cancer (EBC).
501 Background: In the NATALEE clinical trial, RIB + NSAI significantly improved invasive disease–free survival (iDFS) vs...
Development of human B7H3/IL13Ra2 bispecific armored CAR-T for treatment of glioblastoma.
2056 Background: Glioblastoma (GBM) remains a highly lethal malignancy driven by infiltrative growth, molecular complexity...
Pulmonary immune-related adverse events post-immune checkpoint inhibitors (ICI): Real-world experience.
11166 Background: Immunotherapy (IT) has transformed cancer treatment and is often better tolerated than chemotherapy; how...
Race, neighborhood deprivation, and mortality in prostate cancer: A real-world analysis from the MedStar Health Network.
e17137 Background: The Area Deprivation Index (ADI), a validated measure of neighborhood socioeconomic disadvantage, demon...
Clinical and demographic characteristics in ameloblastoma patients: A single-center study.
e18146 Background: Ameloblastomas account for 13-58% of odontogenic tumors. They can be unicystic, extraosseous/peripheral...
Induction adebrelimab combined with chemotherapy followed by response-adaptive concurrent chemoradiotherapy guided by PET-CT in locally advanced unresectable esophageal squamous cell carcinoma: A prospective, single-arm, phase II study.
TPS2692 Background: Concurrent chemoradiotherapy (CCRT) is the standard treatment for locally advanced unresectable esopha...
Prophylactic peptide vaccine targeting resistance mutations in advanced ALK-positive lung cancer: Primary analysis from the ARCHER trial.
8517 Background: Acquired resistance to targeted therapy remains a major challenge in ALK-positive NSCLC and is often medi...
Real-world utilization of upfront genomic testing in newly diagnosed non–small cell lung cancer in a rural state.
e23377 Background: Comprehensive genomic testing (NGS) to inform biomarker-driven therapy is a standard recommendation in...
Efficacy and safety of bevacizumab biosimilars in metastatic colorectal cancer: A pairwise and network meta-analysis.
e15566 Background: Colorectal cancer (CRC) is a significant contributor to cancer-related mortality worldwide. Bevacizumab...
Phase 2 study of YL201, an anti-B7H3 antibody–drug conjugate (ADC), in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC).
5015 Background: The treatment of mCRPC remains challenging, especially for patients who progressed on androgen receptor a...
Tumor and immune microenvironment remodeling with neoadjuvant trastuzumab deruxtecan in HER2-positive gastric cancer: Exploratory analyses from the phase 2 EPOC2003 study.
3129 Background: We previously reported the efficacy and safety of neoadjuvant trastuzumab deruxtecan (T-DXd) for HER2-pos...
Predictors of Gleason score concordance after radical prostatectomy: A SEER analysis.
e17146 Background: Discrepancies between clinical Gleason score (cGS) and pathological Gleason score (pGS) can alter prost...
Trends and disparities in liver cancer–related mortality in adults with psychoactive substance use disorder in the United States, 1999–2023.
e16157 Background: Liver cancer mortality remains a major public health burden in the United States despite advances in pr...
Outcomes with first-line (1L) platinum-based chemotherapy (PBC) and avelumab 1L maintenance in locally advanced or metastatic urothelial carcinoma (la/mUC) by <i>NECTIN4</i> and <i>HER2</i> RNA expression: Exploratory analyses from JAVELIN Bladder 100.
4575 Background: Nectin-4 and HER2 are relevant therapeutic targets and potential biomarkers for the treatment of la/mUC....
Quantitative pathology biomarkers for platinum resistance in ovarian cancer.
5520 Background: Despite serving as the first-line systemic treatment for high-grade serous ovarian cancer, roughly 20% of...
Miconazole as a repurposed therapeutic candidate for prostate cancer.
e17130 Background: Prostate cancer remains a leading cause of cancer-related morbidity and mortality worldwide, despite si...
Comprehensive genomic and clinicopathologic characterization of <i>KRAS</i> G12C– and other <i>KRAS</i> G12–mutated non-colorectal gastrointestinal malignancies.
e16486 Background: Allele-specific KRAS G12C inhibitors have revolutionized lung a...
Real-world insights into bone marrow carcinomatosis in metastatic breast cancer: A retrospective analysis from two large university breast cancer centers.
1104 Background: Bone marrow carcinomatosis (BMC) is a rare but severe manifestation of metastatic breast cancer (mBC) cha...
Molecular landscape of gynecological malignancies in India as associated with distinct MSI and histotype-specific genomic features with therapeutic implications.
e14567 Background: Gynaecological malignancies, including ovarian, endometrial, cervical, uterine sarcoma, and vulvar/vagi...
Clinical efficacy and safety of tiragolumab plus atezolizumab across solid tumors: A meta-analysis of randomized controlled trials.
e14574 Background: Tiragolumab, a first-in-class anti-TIGIT antibody, has emerged as a novel immunotherapeutic strategy in...
Enhanced local and systemic efficacy in refractory solid tumors via integrated intra-tumoral injection and radiotherapy: A study of the ‘R-ISV-RO’ modality.
11558 Background: As for most refractory solid tumors, especially sarcoma, immunotherapy still lacks meaningful improvemen...
Ovarian cancer and hypertension: Changes in comorbidity-related mortality among U.S. women aged ≥45 years, 1999–2023.
e17591 Background: Ovarian cancer causes over 200,000 deaths globally each year, while diabetes mellitus affects more than...